Leonteq Securities AG Makes New $648,000 Investment in Illumina, Inc. $ILMN

Leonteq Securities AG bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the fourth quarter, Holdings Channel.com reports. The fund bought 4,937 shares of the life sciences company’s stock, valued at approximately $648,000.

Other hedge funds have also added to or reduced their stakes in the company. Elyxium Wealth LLC bought a new position in Illumina in the 4th quarter worth about $25,000. Board of the Pension Protection Fund bought a new position in Illumina in the 4th quarter worth about $26,000. Creative Capital Management Investments LLC grew its stake in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. bought a new position in Illumina in the 4th quarter worth about $26,000. Finally, Laurel Wealth Advisors LLC bought a new position in Illumina in the 4th quarter worth about $26,000. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of research analyst reports. Canaccord Genuity Group dropped their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating on the stock in a research note on Friday, May 1st. Weiss Ratings downgraded shares of Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research note on Wednesday, April 29th. Royal Bank Of Canada initiated coverage on shares of Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 target price on the stock. Barclays upped their target price on shares of Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research note on Friday, May 1st. Finally, JPMorgan Chase & Co. upped their target price on shares of Illumina from $120.00 to $125.00 and gave the stock a “neutral” rating in a research note on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $137.75.

Insider Activity at Illumina

In related news, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the completion of the sale, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 104,393 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $145.34, for a total transaction of $15,172,478.62. Following the completion of the sale, the director owned 3,500,048 shares of the company’s stock, valued at approximately $508,696,976.32. This trade represents a 2.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 330,160 shares of company stock valued at $48,028,308 in the last ninety days. Corporate insiders own 2.90% of the company’s stock.

Illumina Price Performance

Shares of ILMN opened at $144.41 on Friday. The company has a 50 day moving average price of $130.45 and a 200-day moving average price of $130.91. Illumina, Inc. has a fifty-two week low of $78.55 and a fifty-two week high of $155.53. The stock has a market capitalization of $21.85 billion, a PE ratio of 26.26, a PEG ratio of 2.40 and a beta of 1.42. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same quarter in the prior year, the company earned $0.97 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.